GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (TSE:2160) » Definitions » Institutional Ownership

GNI Group (TSE:2160) Institutional Ownership : 5.15% (As of May. 19, 2024)


View and export this data going back to 2007. Start your Free Trial

What is GNI Group Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GNI Group's institutional ownership is 5.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GNI Group's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GNI Group's Float Percentage Of Total Shares Outstanding is 0.00%.


GNI Group Institutional Ownership Historical Data

The historical data trend for GNI Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Institutional Ownership Chart

GNI Group Historical Data

The historical data trend for GNI Group can be seen below:

2023-06-30 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 4.28 4.67 5.00 5.04 4.86 4.62 4.79 4.86 5.15 5.15

GNI Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


GNI Group (TSE:2160) Business Description

Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (TSE:2160) Headlines

No Headlines